Study’s Novelty/Excerpt
This study assesses HIV/HCV coinfection and associated risk factors among patients at Specialist Hospital, Sokoto, highlighting the seroprevalence of HCV among HIV/AIDS reactive individuals.
The novelty lies in its detailed demographic analysis, revealing significant age, gender, tribal, educational, and occupational disparities, with a notably high seropositivity among people who inject drugs.
These findings underscore the necessity for targeted HCV screening and intervention strategies in HIV/AIDS patients, particularly in demographic subgroups identified as having higher seroprevalence, to improve early diagnosis and management.
Full Abstract
The Hepatitis C virus (HCV) remains a large healthcare burden. Human Immunodeficiency Virus (HIV) and HCV coinfection are major global health concerns worldwide. This study aimed to assess the HIV/HCV coinfection and the potential risk factors among people attending Specialist Hospital, Sokoto. A cross-sectional seroprevalence survey of HCV infection was carried out on 77 HIV/AIDS reactive subjects attending Specialist Hospital, Sokoto, from 30th March 2021 to 4th May 2021. Serum samples were tested for anti-HCV antibodies using immunochromatographic test. Of the 77 study participants, the overall anti-HCV antibody prevalence was 5.2%. The 36-40 age group revealed the highest seropositivity of 18.18%, followed by 51-55 years (14.29%) and the least (11.11%) among 26-30 years. Females had the highest seropositivity of 6.25% and males least (3.45%). The highest seropositivity was seen among the Hausa tribe (7.14%), while the least in Fulani (5.56%). The highest seropositivity was recorded among people with no formal education (6.82%), while people with formal education had the least (5.88%). The highest seropositivity was seen in self-employed individuals (6.52%) regarding occupational status, while employed individuals had the least (4.17%). Married individuals had the highest seropositivity of 7.69%, while the divorced and widow/widower had 5.26% and 4.76% respectively. People who injected drugs recorded the highest seropositivity of 33.33%, with multiple sex partners at 6.90%, while people who shared sharp objects had the least (6.67%). There were no significant differences statistically in HCV seroprevalence among the different age categories, gender, tribe, education, occupation, marital and risk factors (p>0.05). The HCV prevalence rate (5.8%) observed in this study underscored the need to intensify HCV screening among people living with HIV/AIDS for early diagnosis and management of cases.
